Xconomy

OCTOBER 25, 2017

A new paper from the researchers, published this month in the journal Alzheimer’s & Dementia , is on one level a reminder of decades of research on the cholinergic system—neurons that produce a signaling chemical called acetylcholine.

Research 78

Research Journal San Diego Blogging 78

Xconomy

AUGUST 17, 2016

Histogen, a San Diego-based regenerative medicine company with technology for growing skin cells and related products, said it has raised $6 million from an affiliate of Huapont Life Sciences, a healthcare products company based in Chongqing, China.

Invest 40

Invest San Diego Journal Technical Review 40

Xconomy

SEPTEMBER 27, 2016

Fortis Therapeutics, a new San Diego biotech, has raised $18 million in initial funding to develop drugs for hard-to-treat prostate and bone marrow cancers. San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups).

Avalon 40

Avalon Funding Startup San Diego 40

Xconomy

SEPTEMBER 7, 2016

San Diego-based Retrophin said that its drug, sparsentan, outperformed another drug sometimes used to manage a rare kidney disease, called focal segmental glomerulosclerosis (FSGS), in a Phase 2 clinical trial. He licensed the drug from San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND ) in March 2012. on the Nasdaq.

San Diego 40

San Diego Pricing Study Journal 40

Xconomy

OCTOBER 7, 2016

—Meanwhile, in the wake of the Mylan hearings, the Wall Street Journal this week was the latest outlet to record the animosity between drugmakers and pharmacy benefit managers , the middlemen who buy drugs in bulk for large employers and other insurance payers. . With some caveats, ICER recommended lower prices.

Technical Review 77

Technical Review Study Layoffs San Diego 77

Xconomy

AUGUST 16, 2016

A recent Wall Street Journal article that raised the possibility of Biogen as the target of another huge pharma buyout cited the lack of productivity as a major driver of M&A in the pharmaceutical industry. The authors made the point that, given the size of companies today, a single garden-variety blockbuster hardly moves the needle.

Product 40

Product Journal Venture Capital Demand 40

Xconomy

JUNE 3, 2016

—A team led by Jef Boeke of New York University, George Church of Harvard University, Andrew Hessel of software maker Autodesk, and Nancy Kelley proposed in the journal Science to build a synthetic human genome. billion acquisition of San Diego’s Auspex Pharmaceuticals last year.

San Diego 62

San Diego Patents Acquisition News 62

Xconomy

SEPTEMBER 19, 2016

Charley Grant, writing in The Wall Street Journal , commented that, “Any action to curb price increases on older drugs would hurt manufacturers that rely on them to generate growth.” In his blog Bruce Booth of Atlas Ventures contrasted “exploiters and innovators,” the former a subset of the generic industry.

Pricing 40

Pricing Competition Blogging Journal 40

Xconomy

AUGUST 5, 2016

The Wall Street Journal reported that Cambridge, MA-based Biogen (NASDAQ: BIIB ) has drawn interest from the likes of Merck (NYSE: MRK ) and Allergan (NYSE: AGN ) as a possible takeover target. —Meanwhile, scientists from San Diego-based Synthetic Genomics and the J.

News 40

News Thousand Oaks Pricing Report 40

Xconomy

JULY 17, 2020

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook.

Venture Capital 90

Venture Capital Invest Research Capital 90

socalTECH

FEBRUARY 23, 2009

San Diego-based Newsforce (www.newsforce.com) is a startup which is looking to take advantage of the hunger of the newspaper and media business for revenue, and has created a product which takes press releases and commercial content, and inserts them onto news sites in "sponsored content" blocks. Have you had any issues with that here?

News 124

News Advertising Press Sites 124

Xconomy

APRIL 15, 2019

If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America’s other biomedical hubs. Our goal is to make Columbus the center of the universe for gene therapy,” says Doug Ingram, CEO of Sarepta Therapeutics.

Capital 111

Capital Startup San Diego Journal 111

Xconomy

NOVEMBER 26, 2018

Going deeper into the new world of genetic medicine, the FDA has for the second time approved a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. And more could be on the way.

Design 110

Design San Diego Journal Blogging 110

Xconomy

JULY 8, 2016

British medical journal The Lancet published a study , funded by the Bill and Melinda Gates Foundation, that showed viral hepatitis has become the seventh leading cause of death globally, up from tenth in 1990. —Another health scourge was in the news: hepatitis.

Pricing 52

Pricing News Journal Startup 52

Xconomy

AUGUST 9, 2016

According to the Wall Street Journal, PFWTMs (“people familiar with the matter”) say the new device will look pretty much the same as the iPhone 6s. Apple’s iPhone 7 is due out next month. The biggest change: no more headphone plug.

Software Review 40

Software Review Screening Design Mobile 40

Xconomy

SEPTEMBER 6, 2019

Being first to market with a new type of drug brings advantages. The first mover sets the bar for what physicians, payers, and patients can expect of that medicine and how much it costs. It grabs market share that followers have to steal away. But the first mover isn’t infallible if someone else has something better. is counting on.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

AUGUST 19, 2016

Meanwhile, the latest study reporting that the drugs’ $14,000-a-year list price isn’t cost effective, published this week in the Journal of the American Medical Association , has the drugs’ owners, Amgen (NASDAQ: AMGN ) and Regeneron Pharmaceuticals (NASDAQ: REGN ), up in arms.

Technical Review 40

Technical Review Patents .Net Study 40

Xconomy

MAY 7, 2019

The American Academy of Neurology meeting in Philadelphia is rolling on through the end of this week. There has been plenty of news to digest already. New clinical data could herald cutting-edge treatments for migraine, the rare disease spinal muscular atrophy, the deadly neurological disorder amyotrophic lateral sclerosis, and more.

News 77

News Conference San Diego Journal 77

Xconomy

JUNE 30, 2016

Springer isn’t disclosing Morphic’s discoveries, and the company has yet to publish research in peer-reviewed journals about its work. Thanks in part to better structural biology tools, says Springer, “we think we understand the problem.” ” That’s yet to be proven.

Startup 40

Startup Invest Journal Research 40

SoCal Delicious

OCTOBER 8, 2012

Professor Journal. Student Journal. Developments Blog. Mark Holtzman for The Wall Street Journal. Mark Holtzman for The Wall Street Journal). edition of The Wall Street Journal, with the headline: Tech Titans Hit the Beach. Downtown San Diego Condos. MarketWatch. MarketWatch. AllThingsDigital.

Los Angeles 44

Los Angeles Software Review Technical Review Journal 44

Xconomy

AUGUST 12, 2016

—The status of Sarepta Therapeutics’ (NASDAQ: SRPT ) Duchenne muscular dystrophy drug eteplirsen remains in regulatory limbo, and the Wall Street Journal published this editorial speculating that a “differing-professional-opinions” proceeding—how the FDA clears up internal scientific disputes—might be holding it up.

Google 40

Google Technical Review News Research 40

Xconomy

MARCH 17, 2017

Stung by slow sales of its next-generation anti-cholesterol drug, Amgen hopes new clinical data, released this morning, will spur doctors to boost prescriptions and—perhaps more important—drive insurers to loosen their restrictions. political issue, and pricey new cholesterol drugs have been a key battleground.

Study 87

Study Pricing Sales Journal 87

Xconomy

APRIL 11, 2018

When oncologist Renato Martins finished his medical training, advanced lung cancer was almost certainly a quick death sentence. “I I knew, by name, every patient who had survived two years,” he says. Thanks in large part to the arrival of cancer immunotherapy, things are much different today.

Study 79

Study Training Examples San Diego 79

Xconomy

MAY 30, 2017

When thousands of cancer researchers from around the world gather in Chicago this weekend for the American Society of Clinical Oncology’s annual meeting, drugs that fight tumors by boosting a patient’s immune system will take center stage, as they have in previous years.

Research 84

Research Study San Diego Journal 84

Xconomy

APRIL 16, 2018

[ Editor’s note: Ben Fidler co-authored this report.] A decade from now, it’s possible that immunotherapy will have made a big dent in lung cancer, which is by far the deadliest type of the disease.

Report 69

Report San Diego Study Journal 69

Xconomy

OCTOBER 11, 2016

The company released detailed data at ESMO and published the results in the New England Journal of Medicine. Tesaro released top-line data from this trial in June, and investors cheered the better-than-expected results.

News 40

News Study Report Santa Monica 40

Xconomy

AUGUST 26, 2016

Its latest hike has brought the two-pack of injectors to more than $600, according to the Wall Street Journal. . —Mylan (NASDAQ: MYL ), which last year completed a so-called “tax inversion” to move to the Netherlands and a lower tax bill but still has U.S.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

OCTOBER 28, 2016

—Aaron Kesselheim and Jerry Avorn, both professors of medicine at Harvard Medical School, penned an op-ed in the Journal of the American Medical Association warning of the implications of the FDA’s September decision to approve Sarepta Therapeutics’ Duchenne muscular dystrophy drug eteplirsen (Exondys 51). AND DUCHENNE.

Pricing 40

Pricing Conference News Study 40

Xconomy

APRIL 20, 2017

San Antonio — George Perry, a scientist at the University of Texas at San Antonio, has long proposed that drug developers and researchers need to look earlier into the roots of Alzheimer’s disease.

Study 68

Study Research Develop Development 68

Xconomy

DECEMBER 8, 2017

With 2018 around the corner, this was a week to look ahead. At Xconomy, we zeroed in on several clinical trials that could become major stories in the life sciences. Other healthcare milestones are on the way, too. The FDA will consider for the first time whether a video game should be approved as medicine.

Course 66

Course San Diego Journal Company 66

Xconomy

NOVEMBER 4, 2016

—Doctors testing a combination of two immunotherapy checkpoint inhibitors, nivolumab (Opdivo) and ipilimumab (Yervoy), reported in the New England Journal of Medicine that two melanoma patients in the trial died of heart problems. The companies were expecting a decision by October 30.

Research 40

Research Report Pricing Journal 40

Xconomy

JULY 17, 2018

The enemy of my enemy is my friend—even in the retail and cloud computing businesses. So says retail giant Walmart (NYSE: WMT ) as it announced this morning a five-year partnership with Microsoft (NASDAQ: MSFT ) to use machine learning and other technologies, deepening an existing partnership between two of Amazon’s biggest rivals.

Artificial Inteligence 59

Artificial Inteligence Cloud Computing Press Platform 59

Xconomy

APRIL 20, 2018

The biggest news this week was in oncology, hands down. Merck showed that its immunotherapy pembrolizumab (Keytruda) might become a common option for many patients newly diagnosed with advanced lung cancer, but the bigger picture is that the field is moving fast.

Pricing 52

Pricing News Report Develop 52

Xconomy

MARCH 23, 2018

We’ll start this week’s roundup with several stories from Washington, D.C. that could have a lasting effect on public health. The FDA continued its campaign against cigarettes , while the Centers for Medicare & Medicaid Services (CMS) gave a much-needed boost to the developers of cancer diagnostics.

News 52

News Services Help Develop 52

Xconomy

DECEMBER 1, 2017

A pair of migraine drugs made a splash in biotech news this week with published data suggesting that they can reduce the frequency of headaches. These drugs still await an FDA decision, and their impact on patients over the long term are being watched closely.

News 52

News Research San Diego Journal 52

Xconomy

JUNE 16, 2017

What exactly does the American Health Care Act, the Republican proposal to replace Obamacare, currently look like? Few people know, because the Senate version is being negotiated behind closed doors in Washington D.C. without any public hearings. We do know President Trump now thinks the version of the AHCA that squeaked through the House is “ mean.”

Journal 65

Journal San Diego Blogging 65

Xconomy

NOVEMBER 14, 2017

Poshmark , a social media e-retail company, has raised $87.5 million in a Series D investment round led by Singapore sovereign wealth fund Temasek. That brings the total funding raised by the Redwood City, CA-based company to $160 million.

Social Media 57

Social Media Venture Capital Media Capital 57